Abstract: According to the present invention oil-free vaccines are provided which contain polyoxypropylene-polyoxyethylene polyols as well as an acrylic acid polymer as adjuvating constituents. These vaccines were found to show excellent immunizing properties.

Abstract: The invention is related to a nucleic acid sequence containing the genetic information of the chicken anemia virus (CAV). Especially, three genomic regions are identified encoding viral polypeptides. Said regions or polypeptides can be used for the preparation of a vaccine against CAV infection or for diagnostic purposes. The invention is also concerned with a test kit useful for the detection of CAV infected chickens.

Abstract: A method for imaging foci of infection by administering radiolabeled human IgM 16.88.

Abstract: The invention relates to sulfated glycosaminoglycanoid derivatives of the heparin and heparan sulfate type, of which N-sulfate, N-acetate, and hydroxy groups, are replaced by alkoxy, aryloxy, aralkoxy, or O-sulfate groups. The compounds have antithrombotic and smooth muscle cell proliferation inhibiting activities.

Abstract: The invention relates to sulfated glycosaminoglycanoid derivatives of the dermatan sulfate and chondroitin sulfate type, of which N-sulfate, N-acetate, and hydroxy groups, are replaced by alkoxy, aryloxy, aralkoxy, or O-sulfate groups. The compounds have antithrombotic and smooth muscle cell proliferation inhibiting activities.

Abstract: Disclosed is a process of preparing granules involving first preparing a carrier comprising diluent, binder, and optionally a disintegrating agent. In a container separate from said carrier, a steroid, lubricant and, optionally, an antioxidant are dissolved in an, optionally pre-heated, organic solvent. The resulting solution is added to the carrier contained within an, e.g. vacuum mixer, followed by further blending of the mixture. The organic solvent is removed from the mixture. The mixture is blended further to form granules. The process may further include incorporating a flow enhancer such as colloidal silicon dioxide into the granules. A granule for making a pharmaceutical dosage unit is granule characterized in comprising: a) a carrier comprising diluent and binder, and b) a film coating said carrier, said film comprising desogestrel and a lubricant, and has the characteristic of by retaining 90% of the desogestrel at a pressure of 150 mbar and at a temperature of 70.degree. C. over 72 hours.

Abstract: Disclosed herein is the isolation of a relatively non-pathogenic reovirus, designated strain 2177, and vaccines comprising this strain.

Abstract: The present invention comprises the epitope recognized by the human monoclonal antibody 28A32, the human tumor antigen containing this epitope, which we have identified, isolated and characterized, and human MCA 28A32. The invention also relates to the use of antibodies to the antigen containing this epitope for diagnosis and monitoring of treatment of cancer and to the use of this antigen in the preparation of vaccines to elicit an immune response similar to that obtained against tumor cells containing this epitope.

Abstract: A vaccine and a method of raising neutralizing antibodies against HIV infection. The vaccine comprises a complex of gp120 bonded covalently to CD4 or to succinyl concanavalin A.

Abstract: The present invention relates to monoclonal antibodies, cell lines producing the monoclonal antibodies, assays using the antibodies for the detection of HIV-1 and HIV-2 gene products, and diagnostic kits. More particularly, the monoclonal antibodies react with the p24/p26 capsid protein. Assays using monoclonal antibodies that can simultaneously detect HIV-1 and HIV-2 are disclosed.

Abstract: The invention relates to a use of pregnane derivatives of the following general formula: ##STR1## in which R=H.sub.2, (H,OH), (H,OAcyl), or O, and especially the pregnane derivative(7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor -17-pregn-5(10)-en-20-yn-3-one (compound I), for the manufacture of a medicament for the prevention or treatment of tumors.

Abstract: The invention is a stable liquid thromboplastin reagent used for measuring the performance of the coagulation system, with a shelf life of greater than 16 months, and a method of producing this reagent.

Abstract: An article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances, which wall is made using a biodegradable polymeric material permeable to the active substance, wherein the wall is composed mainly of a combination of at least two different polymeric materials in which one polymeric material is permeable to the active substance and is degradable and the other polymeric material is relatively poorly permeable to the active substance and is degradable and the conveyor path for the delivery of the active substance from the hollow space to the surroundings of the article is a continuous distance leading at least through the polymeric material permeable to the active substance.

Abstract: This invention relates to transformed B-cell lines derived from peripheral blood B-cells of cancer patients actively immunized with autologous tumor antigen and the monoclonal antibodies they produce. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.

Abstract: The present invention is directed to hybridization assays using enzyme-linked oligonucleotide probes, whereby hybridization is detected by separating the hybridized labelled oligonucleotide from the unhybridized probe by gel electrophoresis

Abstract: A method and a device for performing an assay in order to detect or determine the amount of an analyte in a test liquid, wherein bound and unbound reactants can be separated, comprising a capillary canal for liquid transport that is at least partly bordered by a semi-permeable layer, wherein during performance of an assay a movable solid phase material bearing a ligand capable of binding the analyte or binding a reactant for the analyte is within the capillary channel adjacent to the semi-permeable layer, said semi-permeable layer having pores that are sufficiently small to prevent the passage of the movable solid phase material and sufficiently large to permit passage of unbound reactants there through.

Abstract: This invention relates to monoclonal antibody 88BV59 produced by B-cell lines derived from B-cells of cancer patients actively immunized with autologous tumor antigen. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.

Abstract: Disclosed are methods and kits useful in the differential diagnosis of multiple sclerosis. The method involves the use of an immunochemical reagent containing one or more prosomal antigens. Such a method typically involves: obtaining serum from a patient suspected of suffering from multiple sclerosis; contacting the immunochemical agent with the serum; and detecting the presence of immune complexes formed between the prosomal antigen and any antibodies reactive therewith present in the serum.

Abstract: The invention is concerned with a tetrahydropyrimidine derivative having formula I ##STR1## wherein R.sub.1 is hydrogen;R.sub.2 is hydrogen, a lower alkyl group, or lower acyl; orR.sub.1 and R.sub.2 represent together a bond;R.sub.3 is hydrogen, a lower hydrocarbon group optionally substituted with halogen, CN, aryl, or COR.sub.7 ;R.sub.4 is hydrogen, a lower alk(en)yl group, or aryl;R.sub.5 is hydrogen, amino, lower alkyl substituted amino, or a lower alkyl group; andR.sub.6 is hydrogen or methyl;R.sub.7 is amino, lower alkyl substituted amino, or a lower alkyl group; ora pharmaceutically acceptable salt thereof.The compounds of this invention have muscarinic properties and can be used for the treatment of cognition disorders, and for the treatment of cholinergic deficiencies.

Abstract: The present invention is concerned with a recombinant Herpesvirus of Turkeys (HVT), containing a heterologous gene incorporated into an insertion region of the genome of HVT. The invention also relates to a vector vaccine comprising such a recombinant HVT which expresses a heterologous antigenic polypeptide and induces an adequate immune response on infection of an appropriate host animal.